TrialThe Journal of infectious diseases2024

SARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to Remdesivir.

Kanal Singh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.